II
BMRN icon

Inspire Investing’s BioMarin Pharmaceuticals BMRN Stock Holding History

Inspire Investing’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,674
Closed -$453K – 449
2020
Q2 		$453K Sell
3,674
-1,494
-29% -$148K 0.16% 100
2020
Q1 		$437K Sell
5,168
-1,212
-19% -$104K 0.17% 107
2019
Q4 		$539K Buy
6,380
+643
+11% +$48.6K 0.19% 196
2019
Q3 		$387K Buy
5,737
+53
+0.9% +$4.08K 0.15% 204
2019
Q2 		$487K Buy
5,684
+635
+13% +$54.3K 0.2% 188
2019
Q1 		$449K Buy
5,049
+2,089
+71% +$194K 0.21% 179
2018
Q4 		$252K Sell
2,960
-99
-3% -$9.42K 0.17% 189
2018
Q3 		$297K Buy
3,059
+196
+7% +$19.6K 0.18% 170
2018
Q2 		$270K Sell
2,863
-98
-3% -$8.58K 0.19% 167
2018
Q1 		$240K Buy
2,961
+1,126
+61% +$96.6K 0.24% 143
2017
Q4 		$164K Buy
+1,835
New +$160K 0.14% 173

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Inspire Investing's BMRN Position: Q3 2020 in Review

Inspire Investing sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2020, closing a stake of 3,674 shares — an estimated $453K sold.

Inspire Investing first reported a position in BMRN in Q4 2017 and held it in 11 quarters. The position peaked at $539K in Q4 2019. 496 funds tracked by Wall St. Rank hold BMRN as of Q3 2020.

  • Inspire Investing reported no remaining BioMarin Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Inspire Investing sold 3,674 BioMarin Pharmaceuticals shares in Q3 2020, an estimated $453K.
  • Inspire Investing first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 11 quarters.
  • Inspire Investing's BioMarin Pharmaceuticals position peaked at $539K in Q4 2019.
  • 496 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2020.

Based on Inspire Investing's 13F filing for Q3 2020, filed 16 Nov 2020.